OPKO 300

GPTKB entity

Statements (62)
Predicate Object
gptkbp:instanceOf gptkb:Company
gptkbp:activeDuring various biomarkers
gptkbp:administrativeDivision as needed
gptkbp:clinicalTrials high
ongoing
Phase II
ongoing studies
diagnostic imaging
follow established protocols
based on evidence
improved diagnostics
into healthcare systems
specific diagnostic tests
gptkbp:collaborations biotechnology firms
gptkbp:community significant
gptkbp:community_service improved
gptkbp:communityFeedback collected
gptkbp:communityPartnerships academic institutions
gptkbp:contraindication nausea
hypersensitivity to components
gptkbp:date FDA_approved
gptkbp:developedBy gptkb:OPKO_Health,_Inc.
gptkbp:distributionChannels hospitals
gptkbp:educational_programs available for healthcare providers
gptkbp:exportMarkets ongoing
gptkbp:formulation liquid
gptkbp:hasCompetitors other diagnostic products
gptkbp:healthcare high
required
provided
gptkbp:historicalResearch biomarker advancements
https://www.w3.org/2000/01/rdf-schema#label OPKO 300
gptkbp:innovation diagnostic_technology
gptkbp:isFacilitatedBy stringent
gptkbp:label compliant with regulations
gptkbp:lastProduced 2014
gptkbp:manufacturer gptkb:OPKO_Health,_Inc.
gptkbp:market 2015
gptkbp:marketedAs OPKO_Health_brand
gptkbp:marketSegment targeted marketing
gptkbp:packaging vials
gptkbp:partnerships with research institutions
gptkbp:patentStatus patented
gptkbp:priceRange varies by region
gptkbp:productLine diagnostic_products
gptkbp:products continuous
gptkbp:regulatoryBody gptkb:FDA
gptkbp:regulatoryCompliance ensured
gptkbp:research private investors
gptkbp:research_areas oncology
gptkbp:researchFocus biomarker_discovery
gptkbp:route injection
gptkbp:safetyFeatures required
generally safe
gptkbp:sideEffect mild allergic reactions
gptkbp:storage refrigerated
gptkbp:supplyChain multiple suppliers
pharmaceutical distributors
gptkbp:target_audience adults
gptkbp:targetMarket healthcare_providers
gptkbp:training available for practitioners
gptkbp:usedFor diagnosing diseases